- Island Pharmaceuticals (ILA) receives a $1.96 million grant to support phase 2a human trials of ISLA-101 dengue fever treatment
- It was awarded by Congressionally Directed Medical Research Programs to the research foundation for the State University of New York partnered with Island to advance the development of ISLA-101
- The trial evaluates the effectiveness of the drug to treat dengue fever with the funding aiding in the “significant” expansion of data produced in the trial
- Cases of dengue fever have increased more than eight-fold in the last twenty years, with no specific treatment available
- Shares were last trading at 12 cents
Island Pharmaceuticals (ILA) has received a US$1.3 million grant (A$1.96 million) to support phase 2a human clinical trials of its ISLA-101 dengue fever treatment.
The grant was awarded by Congressionally Directed Medical Research Programs to the research foundation for the State University of New York which has partnered with Island to advance the development of ISLA-101.
The trial will evaluate the effectiveness of the drug to treat dengue fever with the funding aiding in the “significant” expansion of data produced in the trial, further characterising Island’s intellectual property.
ISLA-101 is also being repurposed for the prevention and treatment of dengue and other mosquito/vector-borne diseases. Phase 2a is a randomised, double-blind, placebo-controlled study for the prophylactic examination of the dengue challenge model.
Cases of dengue fever have increased more than eight-fold in the last twenty years according to the World Health Organisation, with no specific treatment available.
“The additional supported studies will greatly expand the data we are able to gather through our study and should both advance our understanding of dengue as a disease and facilitate development of products, such as ISLA-101, to bring much-needed relief to patients,” ILA CEO Dr David Foster commented.
Shares in ILA last traded at 12 cents.